NDAORALTABLET1 Generic Approved
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
20
Data completeness
4/8 — Partial
MICARDIS (telmisartan) by Boehringer Ingelheim is angiotensin 2 receptor antagonists [moa]. First approved in 1998.
Drug data last refreshed 1h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MICARDIS (telmisartan) is an oral angiotensin II receptor blocker (ARB) approved in 1998 for hypertension and diabetic nephropathy. It blocks AT1 receptors to reduce vasoconstriction and lower blood pressure, with additional cardioprotective and metabolic benefits. The drug is indicated for hypertension, type 2 diabetes, diabetic nephropathy, dyslipidemia, and other cardiovascular and metabolic conditions.
$2MPart D
LOE ApproachingDeclining
Mature product with declining commercial trajectory; career growth limited as team likely focused on lifecycle management and generic transition planning rather than expansion.
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
Started Jun 2023
116 enrolled
Essential HypertensionMetabolic Syndrome
Efficacy and Safety of Telmisartan Compared With Losartan
Started Apr 2023
98 enrolled
Diabetic NephropathiesHypertension
Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice
Started Jun 2022
0Hypertension
An Observation Study on the Identification of Prescription Patterns of Lodient Tab(Telmisartan/S-amlodipine)
Started Nov 2021
4,000 enrolled
Hypertension
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
Started Jul 2020
156 enrolled
Primary HypercholesterolemiaHypertension
Worked on MICARDIS at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.